glp-1 drugs pharmaceutical companies 2025 How Supply and Demand for Weight Loss is Playing Out in 2026 GLP-1 Drug Market Size &

The safety and tolerability of LY were monitored through vital signs, laboratory data, and adverse events (AEs)

The results of a trial of semaglutide in obese patients with HFpEF showed a significant amelioration of symptoms and improvements in motor function and weight loss compared with patients treated with a placebo

Akkermansia is not a replacement for GLP-1 medications, but it may help support the gut conditions tied to natural metabolic signaling, including mucosal integrity, SCFA production, inflammatory balance, and microbiome resilience

For these patients, insulin therapy with Tresiba may be the preferred option for glucose control

Though several molecules, such as mazdutide, a GLP/glucagon dual agonist, are being studied in various phases, the first agent targeting incretins other than just GLP-1 was approved in 2022 tirzepatide [41]